Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone Density and Turnover in Postmenopausal Women with Osteoporosis
- David M. ReidAffiliated withDepartment of Medicine and Therapeutics, Medical School Buildings, University of Aberdeen Email author
- , David HoskingAffiliated withDepartment of Bone and Mineral Metabolism, Nottingham City Hospital
- , David KendlerAffiliated withClinical Research Centre, St Vincent’s Hospital
- , Maria L. BrandiAffiliated withDepartment of Medicine, University of Florence
- , John D. WarkAffiliated withDepartment of Medicine, Royal Melbourne Hospital, University of Melbourne
- , Georges WeryhaAffiliated withService d’Endocrinologie, Hôpital de Brabois
- , João F. Marques-NetoAffiliated withDepartment of Rheumatology, State University (Unicamp)
- , Keavy A. GainesAffiliated withMerck & Co., Inc.
- , Nadia VerbruggenAffiliated withMerck & Co., Inc.
- and 1 more
- , Mary E. MeltonAffiliated withMerck & Co., Inc.
- Show less
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: The objective of the study was to evaluate the effects of alendronic acid once weekly relative to risedronic acid once weekly on bone mineral density (BMD), markers of bone turnover and tolerability in the treatment of osteoporosis in postmenopausal women.
Methods: This was a randomised, double-masked, double-dummy multicentre international study (75 centres in 27 countries in Europe, the Americas and Asia-Pacific). A total of 1303 women were screened and 936 with low bone density (T-score ≤−2.0 at the spine, hip trochanter, total hip or femoral neck) were randomised; 91% (n = 854) completed the study. Patients were randomised to treatment with either active alendronic acid 70mg weekly (Fosamax®) and placebo identical to risedronic acid weekly or active risedronic acid 35mg weekly (Actonel®) and placebo identical to alendronic acid weekly for 12 months. The primary efficacy endpoint was the percentage change from baseline in hip trochanter BMD at 12 months. Secondary endpoints included the percentage change from baseline in lumbar spine, total hip and femoral neck BMD; biochemical markers of bone turnover (including serum bone-specific alkaline phosphatase [BSAP] and urinary type I collagen N-telopeptides [NTx]); and safety and tolerability as assessed by reporting of adverse experiences.
Results: Alendronic acid produced greater increases in BMD than did risedronic acid at 12 months at all sites measured. Mean percentage increases from baseline in hip trochanter BMD at month 12 were 3.56% and 2.71% in the alendronic acid and risedronic acid groups, respectively (treatment difference [95% CI]: 0.83% [0.22, 1.45; p = 0.008]). Mean percentage increases from baseline were greater with alendronic acid than risedronic acid at the lumbar spine, total hip and femoral neck BMD at month 12 (p = 0.002, p < 0.001, p = 0.039, respectively). Increases in BMD with alendronic acid compared with risedronic acid were also significantly greater at 6 months at the trochanter and total hip. There was a greater reduction in bone turnover with alendronic acid compared with risedronic acid: NTx decreased 58% with alendronic acid compared with 47% with risedronic acid at 12 months (p < 0.001); and BSAP decreased 45% with alendronic acid compared with 34% with risedronic acid at 12 months (p < 0.001). Overall tolerability and upper gastrointestinal tolerability were similar for both agents.
Conclusions: Alendronic acid once weekly produced greater BMD increases at both hip and spine sites and greater reductions in bone turnover relative to risedronic acid once weekly. Both agents were well tolerated with no significant difference in upper gastrointestinal adverse experiences. Clinicians should consider these results when making treatment decisions for postmenopausal women with osteoporosis.
- Alendronic Acid Produces Greater Effects than Risedronic Acid on Bone Density and Turnover in Postmenopausal Women with Osteoporosis
Clinical Drug Investigation
Volume 26, Issue 2 , pp 63-74
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine and Therapeutics, Medical School Buildings, University of Aberdeen, Foresterhill, Aberdeen, AB252ZD, UK
- 2. Department of Bone and Mineral Metabolism, Nottingham City Hospital, Nottingham, UK
- 3. Clinical Research Centre, St Vincent’s Hospital, Vancouver, British Columbia, Canada
- 4. Department of Medicine, University of Florence, Florence, Italy
- 5. Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
- 6. Service d’Endocrinologie, Hôpital de Brabois, Nancy, France
- 7. Department of Rheumatology, State University (Unicamp), Campinas, São Paulo, Brazil
- 8. Merck & Co., Inc., Whitehouse Station, New Jersey, USA